Condition: Childhood Extracranial Germ Cell Tumor · Extragonadal Embryonal Carcinoma · Germ Cell Tumor · Sponsor: Children's Oncology Group
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Children's Hospital of Alabama | Birmingham, Alabama, United States | Recruiting |
| USA Health Strada Patient Care Center | Mobile, Alabama, United States | Suspended |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | Recruiting |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | Suspended |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Recruiting |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | Suspended |
| Katmai Oncology Group | Anchorage, Alaska, United States | Recruiting |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Recruiting |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
| Banner Children's at Desert | Mesa, Arizona, United States | Recruiting |
+ 617 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03067181